Portola Pharmaceuticals, Inc. (PTLA)

Oncology Corporate Profile

Stock Performance

24.6800
-0.4400

HQ Location

270 E. Grand Avenue
South San Francisco, CA 94080

Company Description

Portola Pharmaceuticals is focused on the development and commercialization of novel therapeutics to meet patient needs in thrombosis, other hematologic disorders and inflammation. Our current development-stage portfolio includes wholly-owned and partnered products. Portola's wholly-owned product candidate, cerdulatinib (PRT2070), is an orally available kinase inhibitor that uniquely inhibits two validated tumor proliferation pathways -- spleen tyrosine kinase (Syk) and janus kinase (JAK). It is currently being studied in patients with leukemias or lymphomas with a focus on genetically-defined subtypes, as well as in patients who have failed therapy due to relapse or acquired mutations

Website: http://www.portola.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cerdulatinib / PTR-2070 dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.Chronic Lymphocytic Leukemia (CLL)II
cerdulatinib / PTR-2070 dual tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.Non-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »

Source


http://www.portola.com

Recent News Headlines

Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets

3/9/2017 01:01 pm

[Accesswire] - Upcoming AWS Coverage on Portola Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / March 9, 2017 / Active Wall St. blog coverage looks at the headline from Keryx Biopharmaceuticals, Inc. ...

Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17

3/7/2017 09:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 07, 2017-- Portola Pharmaceuticals Inc. ® today announced that new data from the pivotal Phase 3 APEX Study of the Company’ s investigational drug betrixaban will be ...

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

3/1/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 01, 2017-- Portola Pharmaceuticals, Inc. ® today announced that Bill Lis, chief executive officer, will present at the following conferences in March:. Cowen and Company’ ...

Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update

2/28/2017 09:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017-- Portola Pharmaceuticals, Inc. ® today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2016.. ...

Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28

2/21/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017-- Portola Pharmaceuticals, Inc. ® announced today that it will host a webcast and conference call to discuss the Company’ s financial results for the quarter ...

FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting

2/8/2017 01:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017-- Portola Pharmaceuticals, Inc. ® today announced that the U.S. Food and Drug Administration’ s Center for Drug Evaluation and Research has informed the Company, ...